In the past week, MRNS stock has gone up by 11.95%, with a monthly decline of -15.78% and a quarterly plunge of -84.24%. The volatility ratio for the week is 9.17%, and the volatility levels for the last 30 days are 7.76% for Marinus Pharmaceuticals Inc The simple moving average for the past 20 days is -1.35% for MRNS’s stock, with a -86.32% simple moving average for the past 200 days.
Is It Worth Investing in Marinus Pharmaceuticals Inc (NASDAQ: MRNS) Right Now?
MRNS has 36-month beta value of 1.20. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 7 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MRNS is 41.87M, and currently, short sellers hold a 10.30% ratio of that float. The average trading volume of MRNS on December 26, 2024 was 2.63M shares.
MRNS) stock’s latest price update
Marinus Pharmaceuticals Inc (NASDAQ: MRNS)’s stock price has increased by 6.03 compared to its previous closing price of 0.26. However, the company has seen a 11.95% increase in its stock price over the last five trading sessions. zacks.com reported 2024-11-12 that Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.61 per share a year ago.
Analysts’ Opinion of MRNS
Many brokerage firms have already submitted their reports for MRNS stocks, with Oppenheimer repeating the rating for MRNS by listing it as a “Outperform.” The predicted price for MRNS in the upcoming period, according to Oppenheimer is $6 based on the research report published on September 23, 2024 of the current year 2024.
Robert W. Baird gave a rating of “Neutral” to MRNS, setting the target price at $2 in the report published on April 16th of the current year.
MRNS Trading at -43.19% from the 50-Day Moving Average
After a stumble in the market that brought MRNS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.58% of loss for the given period.
Volatility was left at 7.76%, however, over the last 30 days, the volatility rate increased by 9.17%, as shares sank -14.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -84.18% lower at present.
During the last 5 trading sessions, MRNS rose by +12.97%, which changed the moving average for the period of 200-days by -97.03% in comparison to the 20-day moving average, which settled at $0.2766. In addition, Marinus Pharmaceuticals Inc saw -97.49% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRNS starting from Saraswathy Nochur, who proposed sale 13,250 shares at the price of $0.28 back on Dec 10 ’24. After this action, Saraswathy Nochur now owns shares of Marinus Pharmaceuticals Inc, valued at $3,743 using the latest closing price.
Pfanstiel Steven, the CFO AND COO of Marinus Pharmaceuticals Inc, sale 4,657 shares at $1.13 during a trade that took place back on Aug 05 ’24, which means that Pfanstiel Steven is holding 79,773 shares at $5,262 based on the most recent closing price.
Stock Fundamentals for MRNS
Current profitability levels for the company are sitting at:
- -3.96 for the present operating margin
- 0.89 for the gross margin
The net margin for Marinus Pharmaceuticals Inc stands at -4.46. The total capital return value is set at -4.28. Equity return is now at value -2986.55, with -106.26 for asset returns.
Based on Marinus Pharmaceuticals Inc (MRNS), the company’s capital structure generated -4.78 points at debt to capital in total, while cash flow to debt ratio is standing at -2.08. The debt to equity ratio resting at -0.83. The interest coverage ratio of the stock is -7.28.
Currently, EBITDA for the company is -125.5 million with net debt to EBITDA at -0.11. When we switch over and look at the enterprise to sales, we see a ratio of 0.95. The receivables turnover for the company is 8.19for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.66.
Conclusion
To put it simply, Marinus Pharmaceuticals Inc (MRNS) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
